Cyteir Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYT Nasdaq 8731 https://cyteir.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyteir Therapeutics Inc

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution - Jun 30th, 2023 12:00 pm
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile - Jun 3rd, 2023 1:00 pm
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights - May 10th, 2023 8:01 pm
Insiders who bought Cyteir Therapeutics, Inc. (NASDAQ:CYT) last year must be regretting not buying more as market cap hits US$72m - Apr 20th, 2023 10:30 am
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Mar 23rd, 2023 8:01 pm
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer - Feb 6th, 2023 1:15 pm
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway - Jan 19th, 2023 9:30 pm
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights - Nov 7th, 2022 9:01 pm
Great news for Cyteir Therapeutics, Inc. (NASDAQ:CYT): Insiders acquired stock in large numbers last year - Oct 22nd, 2022 12:34 pm
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium - Oct 12th, 2022 12:00 pm